Piper Sandler analyst Stephen Scouten downgrades FB Financial (NYSE:FBK) from Overweight to Neutral.
Reported Late Thursday Feb 9, Mineralys Therapeutics Announces Pricing Of $192M Upsized Initial Public Offering Of 12M Shares Of Common Stock At A Price Of $16/Share
Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced the pricing of its